Talimogene laherparepvec (T‐VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report

Talimogene laherparepvec (T‐VEC) is a intralesional oncolytic virotherapy, licensed in the European Union for locoregional advanced melanoma of American Joint Committee on Cancer stages IIIB, IIIC and IVM1a. Organ transplant recipients are currently excluded from all clinical trials dealing with imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Ressler, J., Silmbrod, R., Stepan, A., Tuchmann, F., Cicha, A., Uyanik‐Ünal, K., Hoeller, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849788/
https://www.ncbi.nlm.nih.gov/pubmed/30776080
http://dx.doi.org/10.1111/bjd.17783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849788/
https://www.ncbi.nlm.nih.gov/pubmed/30776080
http://dx.doi.org/10.1111/bjd.17783

Ejemplares similares